StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta (SRPT) Phase I/IIa MYO-101 Trial Data 'Striking' - SunTrust
February 27, 2019 11:55 AM
SunTrust analyst Edward Nash reiterated a Buy rating and $176 price target on Sarepta Therapeutics (NASDAQ: SRPT) following 'striking' preliminary ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company
February 28, 2019 6:51 AM
Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen
February 28, 2019 6:21 AM
Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues Miss
February 27, 2019 4:15 PM
Sarepta Therapeutics (SRPT) Announces Positive Expression, Biomarker Data from Three-Patient Cohort Dosed in MYO-101 Gene Therapy Trial to Treat LGMD2E, or Beta-Sarcoglycanopathy
February 27, 2019 9:03 AM
Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Typ
February 27, 2019 9:01 AM
Sarepta Therapeutics (SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing
February 27, 2019 8:16 AM
Sarepta Therapeutics (SRPT) Exercises Option to Acquire Myonexus Therapeutics
February 27, 2019 7:35 AM
Sarepta Exercises Option to Acquire Myonexus Therapeutics
February 27, 2019 7:30 AM
BTIG Expects Sarepta Therapeutics (SRPT) To Pop On Competitor Acquisition
February 25, 2019 8:48 AM
